MariMed Inc. (CSE: MRMD) (OTCQX: MRMD) reported its third-quarter earnings report on Thursday for the three months ended Sept. 30, 2023.

Touted as undervalued when compared to its multi-state operator (MSO) peer by cannabis expert Pablo Zuanic, senior analyst at Zuanic & Associates, MariMed is on track to become a top 10 MSO by 2025.

During the quarter, the company's revenue increased to $38.8 million representing a year-over-year increase of over 14% – a testament to its strong operations in Illinois, Massachusetts, Maryland and Ohio. Upcoming operations are expected in Missouri and Delaware.

Zuanic said on initiating the coverage of the company recently that MariMed maintains strong gross margins, high SGA efficiency and competitive EBITDA margins and that its ability to generate positive operating cash flow sets it apart from many of its peers.

See also: High Capex, High Rewards: Analyst Looks At Cannabis MSOs' Strategies

Q3 Financial Highlights

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.